021-51111890
购物车（）
sales@molnova.cn
AZD 7009 B
CAS No. 335619-18-6
AZD 7009 B ( —— )
产品货号. M34517 CAS No. 335619-18-6
AZD 7009 is a novel antiarrhythmic compound that inhibits the sodium current of hNav1.5 in CHO K1 cells with an IC50 of 11 uM. AZD 7009 inhibited late sodium current in isolated rabbit atrial and ventricular myocytes, and prolonged E-4031-induced action potential duration, promoting early post-depolarization of Purkinye fibers (EADs).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥5387 | 有现货 |
|
| 10MG | ￥7249 | 有现货 |
|
| 25MG | ￥10509 | 有现货 |
|
| 50MG | ￥14229 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AZD 7009 B
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述AZD 7009 is a novel antiarrhythmic compound that inhibits the sodium current of hNav1.5 in CHO K1 cells with an IC50 of 11 uM. AZD 7009 inhibited late sodium current in isolated rabbit atrial and ventricular myocytes, and prolonged E-4031-induced action potential duration, promoting early post-depolarization of Purkinye fibers (EADs).
-
产品描述AZD 7009 is a novel antiarrhythmic compound that inhibits the sodium current of hNav1.5 in CHO K1 cells with an IC50 of 11 uM. AZD 7009 inhibited late sodium current in isolated rabbit atrial and ventricular myocytes, and prolonged E-4031-induced action potential duration, promoting early post-depolarization of Purkinye fibers (EADs).
-
体外实验——
-
体内实验——
-
同义词——
-
通路Membrane Transporter/Ion Channel
-
靶点Sodium Channel
-
受体Sodium Channel
-
研究领域——
-
适应症——
化学信息
-
CAS Number335619-18-6
-
分子量446.54
-
分子式C23H34N4O5
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC([C@@H](COC1=CC=C(C#N)C=C1)O)N2CC3OC(C2)CN(CCNC(OC(C)(C)C)=O)C3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
QX-314 chloride
QX-314 氯化物是一种膜不可渗透的永久带电荷的钠通道阻断剂。
-
CNV1014802
CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine, BIIB074) 是一种有效的选择性 Nav1.7 钠通道阻滞剂。
-
Phenytoin
Phenytoin (5,5-Diphenylhydantoin) 是一种有效的电压门控 Na+ 通道 (VGSCs) 阻滞剂。Phenytoin 具有抗癫痫活性，也可减少小鼠乳腺肿瘤的生长和转移。
